SEC Form 4 · accession 0001232524-17-000183
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Iain McGill
Officer — SVP, Europe & Rest of World
Period of report
Nov 17, 2017
Accepted (ET)
Nov 21, 2017 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Nov 17, 2017 | M | 8,000 | $46.83 | A | 28,383 | D | |
| Ordinary SharesF1 | Nov 17, 2017 | S | 8,000 | $133.4197 | D | 20,383 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $46.83 | Nov 17, 2017 | M | 8,000 | D | — | Aug 8, 2022 | Ordinary Shares | 8,000 | 4,500 | D |
Explanation of responses
- F1Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $132.95 to $133.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2This non-qualified stock option was granted on August 9, 2012 and vested over a period four years from date of grant. The options were fully vested as of August 9, 2016.